Acumen Pharmaceuticals Inc
ABOS1.900USD
-0.130-6.40%
收盤 11/06, 16:00（美東）報價延遲15分鐘
115.09M總市值
虧損本益比TTM
關於 Acumen Pharmaceuticals Inc 公司
Acumen Pharmaceuticals, Inc. 是一家臨牀階段的生物製藥公司。該公司致力於開發一種針對阿爾茨海默病 (AD) 根本病因的疾病改良方法。該公司專注於推進靶向免疫治療候選藥物 sabirnetug (ACU193) 的臨牀開發，該藥物在早期 AD 患者（因阿爾茨海默病病理而患有輕度認知障礙或輕度癡呆的患者）的 I 期結果發佈後進入臨牀開發階段。Sabirnetug 是一種重組人源化免疫球蛋白γ2 (IgG2) 單克隆抗體 (mAb)，可選擇性靶向抗澱粉樣蛋白-β寡聚體 (AbOs)，在體外試驗中已證明具有功能性和保護作用，並在多種動物物種（包括 AD 的轉基因模型）中證明了體內安全性和藥理活性。該公司正在開發用於靜脈 (IV) 給藥的 sabirnetug，每四周給藥一次，用於治療早期 AD。
Acumen Pharmaceuticals Inc簡介
公司代碼ABOS
公司名稱Acumen Pharmaceuticals Inc
上市日期Jul 01, 2021
CEOMr. Daniel J. (Dan) O'Connell
員工數量61
證券類型Ordinary Share
年結日Jul 01
公司地址1210-1220 Washington Street
城市NEWTON
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編02465
電話16173444190
網址https://acumenpharm.com/
公司代碼ABOS
上市日期Jul 01, 2021
CEOMr. Daniel J. (Dan) O'Connell
Acumen Pharmaceuticals Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Mr. Sean Stalfort
Mr. Sean Stalfort
Independent Chairman of the Board
Independent Chairman of the Board
316.72K
+4.21%
Mr. Russell Barton
Mr. Russell Barton
Chief Operating Officer
Chief Operating Officer
136.12K
+40.52%
Dr. Nathan B. Fountain, M.D.
Dr. Nathan B. Fountain, M.D.
Independent Director
Independent Director
19.05K
+204.80%
Dr. Laura Stoppel, Ph.D.
Dr. Laura Stoppel, Ph.D.
Independent Director
Independent Director
12.80K
--
Mr. Daniel J. (Dan) O'Connell
Mr. Daniel J. (Dan) O'Connell
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. James (Jim) Doherty, Ph.D.
Dr. James (Jim) Doherty, Ph.D.
President, Chief Development Officer
President, Chief Development Officer
--
--
Dr. Amy Schacterle, Ph.D.
Dr. Amy Schacterle, Ph.D.
Chief Regulatory Officer, Head of Quality
Chief Regulatory Officer, Head of Quality
--
--
Dr. Jeffrey L. (Jeff) Ives, Ph.D.
Dr. Jeffrey L. (Jeff) Ives, Ph.D.
Independent Director
Independent Director
--
--
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Independent Director
Independent Director
--
--
Mr. Derek Meisner, J.D.
Mr. Derek Meisner, J.D.
Chief Legal Officer
Chief Legal Officer
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Sean Stalfort
Mr. Sean Stalfort
Independent Chairman of the Board
Independent Chairman of the Board
316.72K
+4.21%
Mr. Russell Barton
Mr. Russell Barton
Chief Operating Officer
Chief Operating Officer
136.12K
+40.52%
Dr. Nathan B. Fountain, M.D.
Dr. Nathan B. Fountain, M.D.
Independent Director
Independent Director
19.05K
+204.80%
Dr. Laura Stoppel, Ph.D.
Dr. Laura Stoppel, Ph.D.
Independent Director
Independent Director
12.80K
--
Mr. Daniel J. (Dan) O'Connell
Mr. Daniel J. (Dan) O'Connell
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. James (Jim) Doherty, Ph.D.
Dr. James (Jim) Doherty, Ph.D.
President, Chief Development Officer
President, Chief Development Officer
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 10月24日 週五
更新時間: 10月24日 週五
持股股東
股東類型
持股股東
持股股東
佔比
RA Capital Management, LP
24.65%
Hardie Robert D
5.70%
Sands Capital Ventures LLC
5.64%
PBM Capital Group, LLC
5.29%
Franklin Advisers, Inc.
3.81%
其他
54.91%
持股股東
持股股東
佔比
RA Capital Management, LP
24.65%
Hardie Robert D
5.70%
Sands Capital Ventures LLC
5.64%
PBM Capital Group, LLC
5.29%
Franklin Advisers, Inc.
3.81%
其他
54.91%
股東類型
持股股東
佔比
Venture Capital
29.94%
Hedge Fund
16.95%
Investment Advisor
11.09%
Individual Investor
7.31%
Investment Advisor/Hedge Fund
6.54%
Research Firm
1.84%
Family Office
1.75%
其他
24.59%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
205
40.21M
66.38%
-14.32M
2025Q2
213
49.42M
81.58%
-13.01M
2025Q1
216
49.81M
82.34%
-14.19M
2024Q4
212
52.16M
86.83%
-12.81M
2024Q3
210
53.44M
88.96%
-11.71M
2024Q2
204
53.38M
88.87%
-9.85M
2024Q1
207
53.65M
94.74%
-5.72M
2023Q4
196
47.92M
87.62%
-10.56M
2023Q3
182
52.56M
97.69%
+4.27M
2023Q2
168
35.68M
86.97%
-7.58M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
RA Capital Management, LP
14.93M
24.65%
--
--
Jun 30, 2025
Hardie Robert D
3.45M
5.7%
--
--
Apr 08, 2025
Sands Capital Ventures LLC
3.42M
5.64%
--
--
Jun 30, 2025
PBM Capital Group, LLC
3.21M
5.29%
--
--
Apr 08, 2025
Franklin Advisers, Inc.
3.05M
5.04%
-63.10K
-2.02%
Jun 30, 2025
Fidelity Management & Research Company LLC
2.03M
3.35%
+4.11K
+0.20%
Jun 30, 2025
Millennium Management LLC
1.95M
3.22%
+814.90K
+71.78%
Jun 30, 2025
The Vanguard Group, Inc.
1.69M
2.79%
-247.64K
-12.78%
Jun 30, 2025
Knollwood Investment Advisory, LLC
1.63M
2.69%
--
--
Jun 30, 2025
Pathstone
1.06M
1.75%
-28.00K
-2.58%
Jun 30, 2025
查看更多
持股ETF
更新時間: 18 小時前
更新時間: 18 小時前
機構名稱
佔比
iShares Micro-Cap ETF
0.01%
ProShares Hedge Replication ETF
0%
Avantis US Small Cap Equity ETF
0%
Proshares Ultra Russell 2000
0%
iShares Russell 2000 ETF
0%
iShares Russell 2000 Value ETF
0%
ProShares UltraPro Russell2000
0%
Global X Russell 2000 ETF
0%
iShares Neuroscience and Healthcare ETF
0%
iShares Micro-Cap ETF
佔比0.01%
ProShares Hedge Replication ETF
佔比0%
Avantis US Small Cap Equity ETF
佔比0%
Proshares Ultra Russell 2000
佔比0%
iShares Russell 2000 ETF
佔比0%
iShares Russell 2000 Value ETF
佔比0%
ProShares UltraPro Russell2000
佔比0%
Global X Russell 2000 ETF
佔比0%
iShares Neuroscience and Healthcare ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
